Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and three have issued a strong buy rating

Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers.

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, sixteen have given a buy rating and four have given a

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 581487 shares traded. The stock had previously closed at $366.81. Analyst Upgrades and Downgrades Several analysts recently weighed